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Background: Primary immunodeficiencies (PIDs) are a diverse group of disorders caused
by multiple genetic defects. Obtaining a molecular diagnosis for PID patients using a
phenotype-based approach is often complex, expensive, and not always successful. Next-
generation sequencing (NGS) methods offer an unbiased genotype-based approach, which
can facilitate molecular diagnostics.
Objective:To develop an efficient NGS method to identify variants in PID-related genes.
Methods:We performed HaloPlex custom target enrichment and NGS using the IonTorrent
PGM to screen 173 genes in 11 healthy controls, 13 PID patients previously evaluated with
either an identified mutation or SNP, and 120 patients with undiagnosed PIDs. Sensitivity
and specificity were determined by comparing NGS and Sanger sequencing results for 33
patients. Run metrics and coverage analyses were done to identify systematic deficiencies.
Results: A molecular diagnosis was identified for 18 of 120 patients who previously lacked
a genetic diagnosis, including 9 who had atypical presentations and extensive previous
genetic and functional studies. Our NGS method detected variants with 98.1% sensitiv-
ity and >99.9% specificity. Uniformity was variable (72–89%), and we were not able to
reliably sequence 45 regions (45/2455 or 1.8% of total regions) due to low (<20) average
read depth or <90% region coverage; thus, we optimized probe hybridization conditions
to improve read-depth and coverage for future analyses, and established criteria to help
identify true positives.
Conclusion: While NGS methods are not as sensitive as Sanger sequencing for individ-
ual genes, targeted NGS is a cost-effective, first-line genetic test for the evaluation of
patients with PIDs. This approach decreases time to diagnosis, increases diagnostic rate,
and provides insight into the genotype–phenotype correlation of PIDs in a cost-effective
way.
Keywords: primary immunodeficiency, mutation analysis, Sanger sequencing, next-generation sequencing,
genotype–phenotype correlation, SNV, INDEL
INTRODUCTION
Primary immunodeficiencies (PIDs) are diseases with variable
reported incidence (1/1,200–1/19,000) (1–4), severity, and clinical
phenotype. Those at the severe end of the spectrum lead to life-
threatening infections and life-limiting complications, thus timely
and accurate diagnosis may enable the initiation of specific therapy
that can be lifesaving. Unfortunately, obtaining a genetic diagnosis
for PID patients is often complex for many reasons including (1)
>200 different PID-causing genes have been identified (5); (2) the
clinical phenotype within a genotype can vary significantly; and
(3) more than one genotype can produce similar clinical pheno-
types. One example of the latter is that Mendelian susceptibility to
mycobacterial disease (MSMD, MIM #209950) can be the result
of defects in the genes encoding interferon-gamma receptor-1
Abbreviations: PID, primary immunodeficiency; NGS, next-generation sequenc-
ing; VCF, variant call format; SNV, single nucleotide variant; INDEL, insertion or
deletion
(IFNGR1), interferon-gamma receptor-2 (IFNGR2), the beta-1
chain of the interleukin-12 receptor (IL12RB1), interleukin-12
p40 (IL12B), signal transducer, and activator of transcription-1
(STAT1), as well as other genes.
Today, the most common approach to diagnosing PIDs employs
a phenotype-based approach that includes phenotypic and func-
tional characterization followed by Sanger sequencing of one or
more candidate genes. This canonical approach can be time con-
suming, expensive, and may not always lead to a molecular diag-
nosis. Alternatively, next-generation sequencing (NGS) methods
are becoming increasingly accessible in the clinical laboratory set-
ting (6–8). These rapid, accurate, and relatively low cost methods
allow a high-throughput, genotype-based approach to molecular
diagnosis. For example, targeted sequence enrichment (e.g., Agi-
lent Technologies HaloPlex custom capture kit) followed by NGS
sequencing [e.g., Life Technologies Ion Personal Genome Machine
(Ion PGM)] (9) provides the ability to rapidly screen large panels
of genes. We, therefore, sought to develop a NGS method using
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HaloPlex target enrichment and the Ion PGM for use as a sensitive
and accurate diagnostic tool for simultaneous mutation screening
of known or suspected PID-related genes.
METHODS
SAMPLES
Genomic DNA (gDNA) was extracted from peripheral blood using
standard saline extraction methods. Two hundred twenty-five
nanograms of gDNA were necessary to perform our test. The
validation phases were performed using DNA samples from 11
anonymous healthy adult control subjects (for background fil-
tering) and 13 DNA samples from PID patients with previously
identified gDNA mutations or SNPs. The implementation phase
involved screening 120 PID patients referred without a genetic
diagnosis.
CAPTURE DESIGN
In all, 2455 target regions including the coding exons plus
10 flanking bases of 173 genes known or highly suspected
to be associated to particular PIDs (Table S1 in Supplemen-
tary Material) (1.23 Mbp) were submitted for DNA capture
probe design using the Agilent SureDesign web-based application
(https://earray.chem.agilent.com/suredesign/home.htm). Highly
conserved intronic regions for three genes (CTLA4, CD28, and
GATA2) were also included in the design; however, other non-
coding regions, including promoters and other regulatory regions
were not included. The final probe design was expected to yield
42,909 amplicons covering 99.53% of the submitted target regions.
We were unable to design probes for IKBKG (NEMO), due to the
presence of a pseudogene, or STXBP2 due to the failure of the
SureDesign probe design software to identify probes for >82% of
the coding region; these two genes were, therefore, excluded from
the evaluation.
TARGET ENRICHMENT, LIBRARY PREPARATION, AND NGS
Capture of the target regions was performed with reagents from
a custom design HaloPlex Target Enrichment kit (Agilent Tech-
nologies), according to the HaloPlex Target Enrichment System
Protocol. Briefly, the protocol consisted of the following steps: (1)
digestion of gDNA with restriction enzymes; (2) hybridization of
fragments to probes whose ends are complementary to the tar-
get fragments (during this step, fragments are circularized and
sequencing and barcode adapters are incorporated); (3) capture
of target DNA using streptavidin beads and ligation of circu-
larized fragments; and (4) PCR amplification of captured target
libraries.
Quality control of all libraries was performed on the Agi-
lent Bioanalyzer using a High Sensitivity chip. Template dilutions
were calculated after library concentrations were normalized to
~100 pM using the Ion Library Equalizer kit (Life Technologies).
Library templates were clonally amplified using the Ion One Touch
2™, following the manufacturers’ protocol. Recovered template-
positive ion sphere particles (ISPs) were subjected to enrichment
according to the manufacturer’s protocol. Samples were subjected
to the standard Ion PGM 200 Sequencing v2 protocol using Ion
318 v2 chips (Life Technologies). Up to three samples were loaded
per Ion 318 v2 chip due to variable coverage uniformity.
BIOINFORMATICS ANALYSIS FOR NGS RESULTS
Mapping and variant calling were performed using the Ion Tor-
rent Suite software v3.6. In short, sequencing reads were mapped
against the UCSC hg19 reference genome using the Torrent Map-
ping Alignment Program (TMAP) map4 algorithm. The output
of sequence alignment is a BAM file containing mapped reads.
SNPs and insertions and deletions {INDELS} were called by
the Torrent Variant Caller plugin using default germ line, low
stringency settings [minimum coverage= 6(SNP)/15(INDEL),
minimum coverage each strand 0(SNP)/5(INDEL), minimum
variant score= 10, minimum allele frequency= 0.1, strand bias
0.95(SNP)/0.85(INDEL)] to minimize false negatives; however,
the use of low stringency settings logically increased the number of
known false positives in our datasets. Thus, we identified false pos-
itives (i.e., variants that were predicted to be deleterious but were
present in more than one healthy control) in the datasets for 11
healthy controls. These known false positive variants [Table S2 in
Supplementary Material (BED format)] were then filtered from the
patient’s VCF (variant call format) files, using VCFtools v.0.1.11.
Only reads that were unambiguously mapped were used for variant
calling. Variants were annotated using ANNOVAR (10). Coverage
was evaluated using the Torrent Coverage Analysis plugin and the
output was further evaluated used in-house, custom Perl scripts.
SANGER SEQUENCING
Sanger sequencing was performed to confirm 59 variants (includ-
ing SNPs) detected in 33 patients. gDNA was PCR-amplified
using GoTaq polymerase (Promega) and specific primers (primer
sequences available upon request). Amplicons were bi-directly
sequenced using the Big Dye Terminator version 1.1 cycle sequenc-
ing kit and an Applied Biosystems 3130xl Genetic Analyzer (Life
Technologies).
HYBRIDIZATION OPTIMIZATION
The default HaloPlex probe hybridization protocol includes an ini-
tial denaturation step at 94°C for 10 min. We reasoned that adding
a 2-min 98°C denaturation would boost read depth and coverage
by helping to denature GC-rich and other complex templates. To
test this hypothesis, we ran two different samples in parallel using
the default and modified (98°C) hybridization protocols. Region-
by-region average read depth and percent coverage were compared
using linear regression and the Wilcoxon signed-rank test (paired).
RESULTS
COVERAGE
The gene-by-gene coverage analysis for 33 samples run using the
default HaloPlex probe hybridization protocol is shown in Table
S3 in Supplementary Material and Figure 1. Although the cov-
erage for PIK3CD was expected to be 100%, the actual average
coverage was 94% (85–97%). Unfortunately, one of the poorly
covered regions contains a known hotspot mutation (PIK3CD
c.1573G>A, P.E525K). The coverage for following genes was
expected to be less than 90% based on the probe design: HLA-
DRB5 (82.95%) and NOTCH2 (89.43%). Notably, the Halo-
plex kit is guaranteed to provide >90% coverage for most tar-
get regions; however, the actual coverage for following genes
was suboptimal (less than 90% and more than 5% lower than
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FIGURE 1 | Gene-by-gene coverage analysis for 33 samples run using the default HaloPlex probe hybridization protocol and ion torrent PGM.
FIGURE 2 | Region-by region coverage analysis for 33 samples run using the default HaloPlex probe hybridization protocol and ion torrent PGM.
expected) (expected/actual): HLA-DRB5 (83/29), TNFRSF13C
(100/80), UNC93B1 (95/84), CD79A (100/89), NCF4 (100/89).
The region-by region coverage analysis for 33 samples run using
the default HaloPlex probe hybridization protocol (Table S1 in
Supplementary Material and Figure 2) demonstrates that multiple
regions were systematically poorly covered, including 45 regions
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Table 1 | Run metrics (30 runs, 84 samples).
Chip
density%
Total reads
per chip
Mean raw
accuracy
Q20 bases Mean read
length
Mapped
reads
On target% Mean
depth
Uniformity% Variants
Min 66 3724054 97.8 2106080 72 1147792 64 152 52 74
Max 90 8063266 99.4 398193455 158 3748971 94 921 91 741
Median 77 5859316 99.1 184490059 118 1872132 85 305 85 218
25th percentile 73 5195535 99.0 127030742 113 1553073 80 242 83 150
75th percentile 82 6560932 99.2 236941493 128 2162829 87 425 86 234
(45/2455 or 1.8% of total regions) with low (<20) average read
depth and <90% region coverage.
RUN METRICS
The run metrics for 30 runs (84 samples) using the default
HaloPlex probe hybridization protocol are summarized in Table 1.
ANNOTATION
All single nucleotide variants (SNVs) were correctly annotated
using our in-house bioinformatics pipeline, which utilizes ANNO-
VAR; however, the notation for INDELS was usually incorrect
requiring manual curating. In most cases, it was necessary to per-
form Sanger sequencing to correctly characterize an INDEL, as
characterization of INDELs can be challenging using NGS data.
SENSITIVITY AND SPECIFICITY
We established the sensitivity and specificity of our NGS method
by comparing the results to those obtained by Sanger sequencing
(Table 2 and Table S4 in Supplementary Material). After exclud-
ing exon-flanking regions beyond the+5 and−5 positions, which
were not reliably detected, the false negative rate was 2% (1 false
negative in 52 true positives) indicating a sensitivity of 98.1%.
Since intronic variants located>5 bases from splice sites were not
reliably detected, we have now remedied this by modifying sub-
sequent capture designs to extend the exon-flanking regions to
25 (from 10) bases. Remarkably, we were able to detect a rever-
sion mutation (IL2RG c.460C>T, p.P154S; patient I10) that was
present in only 3% of the alleles as the coverage was fairly deep at
the variant position (depth= 257); however, this was detected only
after reanalyzing the dataset without using an alternate allele fre-
quency cut-off. Nonetheless, our method is not sensitive enough
to reliably detect rare somatic alleles due to the non-uniformity of
coverage. All of the false negative variants (including the intronic
false negative variants) could be attributed to low coverage.
The false positive rate was <0.1% (2 false positives among
59,012 true negative bases) indicating a specificity of >99.9%.
One of the false positives was also present in datasets from other
samples in the same run indicating that it was likely an artifact.
The other false positive (GATA2 c.1-2067C>T) was due to the
presence of a homopolymer run. Both false positive changes were
ruled out by bidirectional Sanger sequencing.
Based on our experience during the validation and implemen-
tation phases of our study, we have identified useful criteria for
identifying high probability SNV calls, that is, those calls that are
likely to be true positives (Table 3). If a SNV meets these criteria,
we feel that Sanger sequencing confirmation is not warranted as
Table 2 | Summary of comparison of NGS and Sanger sequencing
results (n=33 samples).
True positives 52 True negatives 59012
False negatives 1 False positives 2
False negative rate 1.9 False positive rate 0.003
Sensitivity (exonic) 98.113 Specificity 99.997
Table 3 | Criteria for identifying highly likely true positives.
Base caller Phred-based q score ≥30
Total read depth ≥20
Variant allele frequency ≥25%
Coverage is too low for reliable detection of somatic variants
BAM file should be manually inspected if somatic variant is suspected
Variant is not present in any wild-type controls
Variant is not present in other samples within same run (i.e., samples from
patients with different phenotypes)
No other variants (SNVs or INDELS) are present within the same reads
containing the variant allele
Variant is not contained within or immediately adjacent to a homopolymer
run or repeat region
Variant is not an INDEL
All INDELS must be confirmed by an independent method (e.g., Sanger
sequencing)
the variant is highly likely to be a true positive. Alternatively, all
SNVs that do not meet these criteria and all INDELs must be
confirmed by an independent method (e.g., Sanger sequencing).
DIAGNOSTIC EFFICIENCY
The diagnostic efficiency of our targeted NGS method for detect-
ing PIDs was demonstrated by our ability to obtain a molecular
diagnosis for 18 of 120 (15%) patients who previously lacked a
genetic diagnosis, including 9 who had extensive previous genetic
and functional studies.
HYBRIDIZATION OPTIMIZATION
We optimized the HaloPlex probe hybridization by adding
of a 2-min 98°C denaturation step. This simple modification
boosted median average read depths significantly from 142 to
182 in two samples tested in parallel (Wilcoxon signed-rank test
V = 18,89,459, p-value< 2.2e-16; Table 4; Figure 3). While the
median and interquartile range for percent coverage did not appear
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to be different among protocols, the Wilcoxon signed-rank paired
test showed that an increased percent coverage resulted from
the optimized protocol (V = 52,943.5, p-value< 2.2e-16; Table 4;
Figure 4). The coverage of some regions was decreased using the
modified protocol; however, these regions were fewer than those
that showed the same or increased coverage (Figure 4). Notably,
the optimized protocol yielded 179 fewer flagged regions (i.e.,
regions with an average coverage of <20 reads and/or regions
that are <100% covered). Unfortunately, the region encoding
the PIK3CD E525K hotspot mutation was not rescued by our
optimized probe hybridization protocol.
TARGETED NGS vs. SANGER SEQUENCING REAGENT COSTS
We compared reagent costs for our targeted NGS method (Halo-
plex/Ion Torrent PGM) and various Sanger sequencing analy-
ses (Table 5). The reagent cost for our targeted NGS method
is approximately $580 per sample, while the reagent cost for
Sanger sequencing is approximately $10 per amplicon. Our
data show that targeted NGS is a cost-effective alternative to
Sanger sequencing in terms of reagent cost for complex dis-
eases requiring >60 amplicons (e.g., DOCK8 deficiency) and for
diseases associated with multiple candidate genes [e.g., autoim-
mune lymphoproliferative syndrome (ALPS), severe combined
Table 4 | Descriptive statistics for average read depth and % coverage per region for two samples run in parallel using the default and optimized
hybridization protocol.
Default hybridization Optimized hybridization Difference Wilcoxon signed-rank
protocol protocol (2-min 98°C (optimized-default) test (paired)
denaturation)
Flagsa 845 666 −179
Median average read depth 142 182 40 V =1889459, p-value <2.2e-16
25th percentile average read depth 75 104 29
75th percentile average read depth 230 286 56
Minimum average read depth 0 0 0
Maximum average read depth 1267 1293 26
Median % coverage 100 100 0 V =52943.5, p-value <2.2e-16
25th percentile % coverage 100 100 0
75th percentile % coverage 100 100 0
Minimum % coverage 0 0 0
Maximum % coverage 100 100 0
Regions 4784 4784 0
aRegions with an average coverage of <20 reads and/or regions that are <100% covered were flagged.
FIGURE 3 | Average read depth compared (default hybridization protocol vs. addition of 2-min 98°C initial denaturation).
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FIGURE 4 | Percent coverage compared (default hybridization protocol vs. addition of 2-min 98°C initial denaturation).
Table 5 | Maximal reagent costs of targeted NGS vs. Sanger sequencing of genes included in the sequence capture design.
Phenotype Genes (amplicons) Total Sanger sequencing Targeted NGS
amplicons for all listed (HaloPlex/Ion
genes Torrent PGM)
DOCK8 deficiency DOCK8 (62) 62 $620 $580
Medalian susceptibility to mycobacterial
disease (MSMD)
IFNGR1 (8), IFNRG2 (8), IL12RB1 (17), IL12B (7), ISG15
(3), STAT1 (21), IRF8 (16), GATA2 (15), CYBB (20)
115 $1,150
Immunodeficiency with hyper-IgM (HIGM) CD40LG (8), CD40 (12), ICOS (5), PIK3CD (18), AICDA
(5), NFKBIA (7)
55 $550
Autoimmune lymphoproliferative
syndrome (ALPS) and ALPS-like diseases
FAS (9), FASL (4), CASP8 (10), CASP10 (11), NRAS (4),
KRAS (5), CTLA4 (8), PIK3CD (18)
69 $690
Severe combined immunodeficiency
(SCID)
CD3D (6), CD3E (11), DCLRE1C (29), ORAI1 (6), ADA
(12), IL2RG (8), IL7R (14), NHEJ1 (8), PTPRC (40),
RAG1 (7), RAG2 (4), JAK3 (18), CORO1A (14),PRKCD
(22), AK2 (18)
199 $1,990
immunodeficiency (SCID), hyper-IgM syndrom-(HIGM), and
MSMD]. It is important to note, however, that this cost analy-
sis does not include the cost of the labor, which far outweighs
reagent costs, particularly for low-throughput methods such as
Sanger sequencing.
DISCUSSION
Our results demonstrate that the Haloplex custom target
enrichment in combination with Ion Torrent PGM sequencing
provides a sensitive and specific NGS method for the identification
of mutations in PID-related genes, overcoming the complexity
of the phenotype-based, candidate gene approach. Indeed, this
approach will provide more insight into genotype–phenotype
correlations for PIDs.
Nonetheless, our study illustrates that identification of disease-
causing genetic defects in patients with PIDs using targeted NGS
is still a major challenge, requiring protocol optimization, back-
ground and quality metrics-filtering, and manual quality con-
trol (visual inspection of the alignment file). Although we opti-
mized the HaloPlex probe hybridization protocol, the potential
for false negatives due to variable coverage is a cause for con-
cern in the clinical setting. The systematically poor coverage that
we observed for some regions was probably due to regional dif-
ferences in local sequence chemistry, which may include high
GC-content, repeat regions, and highly homologous sequences,
which confound probe hybridization and read mapping. These
are well-recognized limitations of most sequencing methods,
including Sanger sequencing; however, in a diagnostic setting,
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it is imperative to identify which genomic regions have inad-
equate coverage, especially those exons containing mutational
hotspots. All failed regions should be clearly identified in the clin-
ical report, and further evaluation of clinically relevant regions
should be performed by Sanger sequencing or another comple-
mentary method to exclude pathogenic mutations. Moreover, a
targeted NGS approach will only identify defects affecting genes
or exon-boundaries regions included in the test panel. Intronic,
promoter, and regulatory region associated changes or low copy
number somatic variants would not be detected through this
method. Likewise, large insertions, deletions, and other chromo-
somal abnormalities are not detectable by current sequencing
strategies including Sanger sequencing and need to be dealt with
using techniques that focus on copy number variation. Finally,
unless a variant has been previously characterized as associated
with a specific PID, functional assays are still necessary to prove
causality between a gene variant and a clinical phenotype.
Regarding result confirmation, the American College of Med-
ical Genetics guidelines state that NGS result confirmation is
essential when the analytic false positive rate is high or not yet
well established, particularly in whole exome and whole genome
sequencing approaches (11). For targeted NGS methods, it is
practical to analyze multiple normal controls so as to identify
platform-specific false positive variants and then filter these vari-
ants from subsequent analyses. In our experience, this practice of
background filtering resulted in a low FP rate and >99.9% speci-
ficity for our targeted NGS method, thereby reducing the need for
independent confirmation of SNVs, as long as they the criteria for
high probability SNV calls (Tables 2 and 3). All variants that do
not meet these criteria, including all INDELS, should be confirmed
by an independent method.
Our reagent cost comparison shows that targeted NGS is a
cost-effective alternative to Sanger sequencing for complex dis-
eases requiring >60 amplicons (e.g., DOCK8 deficiency) and for
diseases associated multiple candidate genes (e.g., ALPS, SCID,
HIGM, and MSMD). It is also likely to be efficient for evaluat-
ing atypical syndromes that can be associated with mutations in
genes typically associated with more classical phenotypes (12).
Moreover, it is important to note that the cost of labor needed to
perform DNA sequencing and analysis far outweighs reagent costs,
and high-throughput NGS methods are associated with reduced
labor costs compared to Sanger sequencing. Thus, NGS is a cost-
effective alternative to Sanger sequencing for molecular diagnosis
of PIDs, except when testing for known family mutations based
on a focused evaluation of a single amplicon.
In summary, targeted NGS methods such as the one described
above can be used as a cost-effective first-line genetic test for evalu-
ation of new cases of PIDs; however, results should be considered
in the context of a region-by-region coverage report, and sec-
ond line testing to exclude disease-causing mutations should be
performed if warranted (i.e., when coverage is poor for a gene
that is a good candidate based on phenotype). In many cases,
this approach will facilitate diagnosis compared to the phenotype-
based approach. The diagnostic yield is likely to be the highest in
cases when the clinical presentation is atypical; for patients with
PIDs that exhibit a large genotype–phenotype variability or vari-
able penetrance; and for PIDs in which defects in multiple genes
can cause the same phenotype.
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